Paper Details

  1. Home
  2. Paper Details

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

Author: , BonkovskyHerbert L, Di BisceglieAdrian M, DienstagJules L, EverhartJames E, EversonGregory T, GhanyMarc G, GoodmanZachary D, LeeWilliam M, LindsayKaren L, LokAnna S, MorganTimothy R, MorishimaChihiro, ShiffmanMitchell L, WrightElizabeth C

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Peginterferon alfa-2a and ribavirin were effective in achieving sustained virologic response (SVR) in selected nonresponders to previous interferon-based therapy for chronic hepatitis C virus (HCV) infection.
Paper Details　
Original Abstract of the Article :
BACKGROUND & AIMS: The most effective therapy currently available for treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin. This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy. MET...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/j.gastro.2004.01.014

データ提供：米国国立医学図書館（NLM）

Peginterferon alfa-2a and Ribavirin: A New Oasis in the Treatment of Hepatitis C

The treatment of chronic hepatitis C is a complex and challenging journey, much like navigating a vast and unforgiving desert. This study focuses on the effectiveness of peginterferon alfa-2a and ribavirin, a combination therapy, in patients who had previously failed treatment for hepatitis C. The authors meticulously analyzed data from a large clinical trial, like a caravan carefully examining the trails left by previous expeditions, to assess the efficacy of this treatment approach. Their findings suggest that this combination therapy can offer a new path to sustained virologic response (SVR), a measure of the success of treatment, in a subset of patients who had previously struggled to overcome the disease. It's as if the combination therapy acts as a well-hidden oasis in the desert, providing a chance for healing and recovery for those who have previously failed to find a cure.

A Second Chance in the Hepatitis C Desert

The study reveals that peginterferon alfa-2a and ribavirin can achieve SVR in a significant percentage of patients who had previously failed treatment, a finding that offers hope and renewed possibility in the struggle against hepatitis C. This is like discovering a previously unknown oasis in a desert, offering a chance for survival and prosperity.

Navigating the Hepatitis C Landscape

This study underscores the importance of individualized treatment approaches for chronic hepatitis C, as not all patients respond to therapy in the same way. Just as different paths lead to different oases, the optimal treatment strategy for each patient may vary. The authors also highlight the importance of ongoing research to improve treatment outcomes for those living with hepatitis C.

Dr.Camel's Conclusion

Peginterferon alfa-2a and ribavirin offer a new oasis in the desert of hepatitis C treatment, providing a chance for sustained recovery in patients who had previously failed treatment. This study underscores the importance of individualized treatment approaches and the ongoing need for research to conquer this challenging disease.

Date :
  1. Date Completed 2004-05-11
  2. Date Revised 2019-07-07
Further Info :

Pubmed ID

15057741

DOI: Digital Object Identifier

10.1053/j.gastro.2004.01.014

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.